ranimustine has been researched along with methylprednisolone in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sakai, C; Takagi, T; Tamaru, J; Tsujimura, H | 1 |
Imai, K; Kawamura, T; Kondo, K; Sakurai, H; Sato, T; Takemori, N | 1 |
Chiba, S; Hasegawa, Y; Matsumura, A; Okoshi, Y; Sakamoto, N; Takano, S; Taoka, K | 1 |
3 other study(ies) available for ranimustine and methylprednisolone
Article | Year |
---|---|
Involvement of the appendix in a relapsed case of primary nasal NK/T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Appendicitis; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Humans; Intestinal Perforation; Killer Cells, Natural; Leucovorin; Lymphoma, T-Cell; Male; Methotrexate; Methylprednisolone; Nitrosourea Compounds; Nose Neoplasms; Prednisone; Skin Neoplasms; Splenic Neoplasms; Tumor Virus Infections; Vincristine | 2000 |
Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Glucocorticoids; Humans; Immunoglobulin D; Immunoglobulin lambda-Chains; Interferons; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nitrosourea Compounds; Prednisolone; Remission Induction; Vincristine | 2001 |
A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Lymphoma; Male; Methotrexate; Methylprednisolone; Middle Aged; Nitrosourea Compounds; Procarbazine; Retrospective Studies | 2010 |